InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business – Read More
Your Discovery &
Preclinical Partner.
Tailored discovery Strategies. Translational research models. Results that drive development.
200+ Customers
LOCAL EXPERTISE, GLOBAL SUPPORT
Access our strong network of preclinical services to support your study, wherever you are.Â
UPFRONT COSTS
Transparent pricing so you can budget with confidence. No hidden fees or unexpected price changes.
TRUE FLEXIBLE RESEARCH
We tailor our processes to meet your specific research needs. No one-size-fits-all approach.
DEDICATED STUDY MANAGEMENT
Work directly with niche experts who understands your study, ensuring clear communication and efficient execution.
SCIENTIST TO SCIENTIST COLLABORATION
Full project support from ideation, design and implementation to post-study consultations on your future research.
DEFINED MILESTONES, CLEAR RESULTS
Access your data when you expect it. Secure real time data sharing from your research.
Nonclinical research is complex and demanding, we bring the expertise and structure to support you as an extension of your team.
Breeding and on-site colony management and line storage
Access to curated preclinical ecosystem
Model validation expertise
Personalized study management and dedicated team
Custom study design and consultations
Transparent communication throughout study
✓
✓
✓
✓
✓
✓
Traditional CRO
–
–
–
–
–
–
Oncology
InnoSer’s oncology team possesses experience working with multiple oncology therapy types ranging from novel delivery methods, oncology vaccines, immuno-oncology targets, combination therapy, small molecules, biologics to cell and gene therapy approaches.
Immunology
InnoSer works with well-published in vitro and in vivo models relevant for multiple indications ranging from hypersensitivity, inflammatory, to autoimmune diseases. Choose InnoSer as your CRO, and you’ll work alongside our study directors who take a collaborative approach for your study.
Neurology
InnoSer offers an integrated neurology CRO services portfolio spanning from in vitro to in vivo research services. Our experts accelerate your drug development process using in-depth knowledge of the models in our portfolio to provide reliable experimental data.Â
Rare Disease
InnoSer supports rare disease research with a specialized portfolio of preclinical models designed to mimic key disease pathophysiology. With dedicated facilities and skilled personnel, we provide reliable execution of complex procedures, advanced imaging, and biomarker analyses, delivering high-quality data with flexible study start-up times.
Metabolic
InnoSer offers you a portfolio of multiple gold-standard mouse models of common metabolic diseases of different etiologies, ranging from obesity, type 2 diabetes mellitus (T2DM) and their common associated complications such as cognitive dysfunction and/or cardiac dysfunction.
Cardiovascular
InnoSer, offers gold-standard mouse models for common cardiovascular diseases and heart failure (HFrEF & HFpEF). With expert disease modeling, specialized facilities, and skilled personnel, we ensure reliable cardiac surgeries, technical procedures, and flexible study start-up times for robust data.
Disease Area Expertise
Connect With Experts in Your Niche.
Housing and Colony Management
Our team specializing in genetically modified animal models supports you in identifying, developing, and managing the most suitable mouse strains for your research needs. We offer comprehensive services including the generation of custom mouse models, colony breeding and management, genetic validation, and long-term preservation through embryo and sperm cryostorage.
Reliable, Consistent Supply of Research-Ready Models
Ensure uninterrupted access to healthy and well-characterized animals with expertly managed breeding programs tailored to your research timelines and study requirements.
High-Quality Animal Care and Welfare Standards
Benefit from professional husbandry practices, accredited facilities, and stringent health monitoring to maintain the integrity and reproducibility of your data.
Scalable, Customized Colony Support
From small pilot studies to large-scale preclinical programs, receive flexible, end-to-end support including colony expansion, genotyping, and cryopreservation, all adapted to your specific model needs.
Discovery
The discovery phase is critical for identifying and validating novel therapeutic candidates. At InnoSer, we support this process by providing scientifically robust models and tailored services that help you generate reproducible, decision-driving data. Our goal is to help you confidently select lead compounds and progress the most promising candidates into preclinical development.
In Vitro Screening and Mechanism-of-Action Studies
Utilize our cell-based assays, organoid models, and high-content imaging platforms to evaluate compound efficacy, cytotoxicity, and mechanisms of action in relevant biological systems.
Early In Vivo Proof-of-Concept Models
Engage with our portfolio of validated mouse models—including oncology, neurodegenerative, and inflammatory disease models—to assess in vivo efficacy, dosing strategies, and pharmacodynamic biomarkers.
Biomarker and Histopathological Analysis
Strengthen your findings with detailed tissue analyses, including immunohistochemistry, histology, and molecular readouts, supported by our experienced pathology and bioanalysis teams.
Optimization
Fine-tune your lead candidates by assessing efficacy, dosing, safety, and pharmacokinetics to prepare for regulatory preclinical studies. At InnoSer, we support this process with well-established models, customized study designs, and detailed analyses that help you confidently advance the best version of your candidate toward IND-enabling studies.
Dose-Response and Treatment Regimen Evaluation
Design and execute tailored in vivo studies to determine optimal dosing strategies, treatment schedules, and therapeutic windows using clinically relevant disease models.
Pharmacokinetic and Pharmacodynamic (PK/PD) Assessments
Gain insight into compound behavior through bioanalytical services that assess exposure, distribution, and biological activity, enabling data-driven adjustments to formulation or dosing.
Non-GLP Toxicity and Tolerability Profiling
Mitigate development risks by identifying early safety signals through MTD studies, single-dose response, and histopathology assessments and more, providing crucial insights to guide lead candidate selection.Â
Preclinical
At InnoSer, we specialize in late-stage non-GLP preclinical studies that deliver meaningful insights to guide your candidate selection and next development steps. From advanced efficacy testing and dosing strategy refinement to resistance and combination studies, our team ensures your compound is backed by robust, translational data.
CUSTOM STUDIES TO DE-RISK YOUR PIPELINE
InnoSer’s fit-for-purpose studies help you confirm mechanism of action, assess preliminary efficacy, and validate disease relevance. These cost-effective studies provide critical data to support go/no-go decisions.
Route of Administration and Dosing Refinement
Explore different administration routes (e.g., IV, SC, IP) and dosing regimens to optimize therapeutic exposure, align with intended clinical protocols, and support translational relevance.
Efficacy Validation in Predictive Models
Confirm and strengthen therapeutic potential through extended or repeat-dose studies in validated, clinically relevant models, supporting robust candidate selection and investment decisions.
Join The Team
Support scientific discoveries that shape the future of healthcare.
Our Latest News
InnoSer and CureSHANK partner to launch industry-quality preclinical testing service for Phelan-McDermid syndrome (PMS) treatments
Together, CureSHANK, a nonprofit research foundation, and InnoSer, preclinical research CRO, aim to remove barriers to drug development for Phelan-McDermid syndrome treatment by providing the global research community with accessible and industry-standard preclinical...
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
As part of our ongoing efforts to support the development of new therapeutics for rare genetic neurological diseases, we are proud to introduce a new preclinical research model for Angelman Syndrome within InnoSer’s portfolio. In collaboration with Professor Ype...
InnoSer Partners with Kabuki Syndrome Foundation to Advance Therapeutic Development for Kabuki Syndrome
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model. This collaboration aims to empower leading biotech and pharma innovators to perform rigorous studies informing clinical trial readiness of...
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. Â The ADPD 2025 Conference is...
Ready to work with a CRO that’s as committed as you are?
Join us in delivering impactful studies that bring therapies to patients sooner.
info@innoserlaboratories.com